Title : Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.

Pub. Date : 2018 Aug 24

PMID : 30145562






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF). Simeprevir beta-1,4-galactosyltransferase 1 Homo sapiens
2 INTRODUCTION AND AIM: Approximately 10%-15% of patients with hepatitis C genotype 1 (HCV GT1) experience virological relapse after all-oral antiviral regimen using simeprevir (SMV) and sofosbuvir (SOF). Simeprevir beta-1,4-galactosyltransferase 1 Homo sapiens
3 CONCLUSIONS: Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. Simeprevir beta-1,4-galactosyltransferase 1 Homo sapiens